Executive Summary Three decades of aggressive outsourcing to low-cost geographies suppressed the Cost of Goods Sold (COGS) for Active Pharmaceutical […]

Section 1: The Patent Cliff, Defined and Reframed What the Term Actually Means The phrase ‘patent cliff’ describes the sharp

Why Generic Drug Market Analysis Fails — and How to Fix It Most generic drug market analyses make the same

A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar

1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in

Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term

The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file

There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a

Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The